These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 35776238)

  • 1. What Do Randomized Controlled Trials Inform Us About Potential Disease-Modifying Strategies for Parkinson's Disease?
    Ong WY; Leow DM; Herr DR; Yeo CJ
    Neuromolecular Med; 2023 Mar; 25(1):1-13. PubMed ID: 35776238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective strategies in Parkinson's disease : an update on progress.
    Mandel S; Grünblatt E; Riederer P; Gerlach M; Levites Y; Youdim MB
    CNS Drugs; 2003; 17(10):729-62. PubMed ID: 12873156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
    Oertel W; Schulz JB
    J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease.
    Perez-Lloret S; Otero-Losada M; Toblli JE; Capani F
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1163-1173. PubMed ID: 28836869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.
    Schapira AH
    CNS Drugs; 2011 Dec; 25(12):1061-71. PubMed ID: 22133327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease modification in Parkinson's disease.
    Henchcliffe C; Severt WL
    Drugs Aging; 2011 Aug; 28(8):605-15. PubMed ID: 21812497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A zebrafish screen reveals Renin-angiotensin system inhibitors as neuroprotective via mitochondrial restoration in dopamine neurons.
    Kim GJ; Mo H; Liu H; Wu Z; Chen S; Zheng J; Zhao X; Nucum D; Shortland J; Peng L; Elepano M; Tang B; Olson S; Paras N; Li H; Renslo AR; Arkin MR; Huang B; Lu B; Sirota M; Guo S
    Elife; 2021 Sep; 10():. PubMed ID: 34550070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The principal molecular mechanisms behind the activation of Keap1/Nrf2/ARE pathway leading to neuroprotective action in Parkinson's disease.
    Chakkittukandiyil A; Sajini DV; Karuppaiah A; Selvaraj D
    Neurochem Int; 2022 Jun; 156():105325. PubMed ID: 35278519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.
    Caslake R; Macleod A; Ives N; Stowe R; Counsell C
    Cochrane Database Syst Rev; 2009 Oct; (4):CD006661. PubMed ID: 19821381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline.
    Gerlach M; Desser H; Youdim MB; Riederer P
    J Neural Transm Suppl; 1996; 48():7-21. PubMed ID: 8988458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective therapies.
    Simon DK; Standaert DG
    Med Clin North Am; 1999 Mar; 83(2):509-23, viii. PubMed ID: 10093591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unveiling Nature's potential: Promising natural compounds in Parkinson's disease management.
    Bhusal CK; Uti DE; Mukherjee D; Alqahtani T; Alqahtani S; Bhattacharya A; Akash S
    Parkinsonism Relat Disord; 2023 Oct; 115():105799. PubMed ID: 37633805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine agonists and neuroprotection in Parkinson's disease.
    Olanow CW; Jenner P; Brooks D
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S167-74. PubMed ID: 9749590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
    Clarke CE
    Mov Disord; 2004 May; 19(5):491-8. PubMed ID: 15133811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease.
    Faust K; Gehrke S; Yang Y; Yang L; Beal MF; Lu B
    BMC Neurosci; 2009 Sep; 10():109. PubMed ID: 19723328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole.
    Albrecht S; Buerger E
    Curr Med Res Opin; 2009 Dec; 25(12):2977-87. PubMed ID: 19842998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are dopamine receptor agonists neuroprotective in Parkinson's disease?
    Le WD; Jankovic J
    Drugs Aging; 2001; 18(6):389-96. PubMed ID: 11419913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease.
    Radad K; Gille G; Rausch WD
    Pharmacol Rep; 2005; 57(6):701-12. PubMed ID: 16382188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plant Polyphenols as Neuroprotective Agents in Parkinson's Disease Targeting Oxidative Stress.
    Hor SL; Teoh SL; Lim WL
    Curr Drug Targets; 2020; 21(5):458-476. PubMed ID: 31625473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotection in Parkinson's disease: an elusive goal.
    Koller WC; Cersosimo MG
    Curr Neurol Neurosci Rep; 2004 Jul; 4(4):277-83. PubMed ID: 15217541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.